Lorigerlimab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Lorigerlimab
DrugBank Accession Number
DB18942
Background

Lorigerlimab is under investigation in clinical trial NCT05848011 (A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-resistant Prostate Cancer).

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • IMMUNOGLOBULIN, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN-MUS MUSCULUS CLONE MG13.78 .KAPPA.-CHAIN V-J REGION) FUSION PROTEIN WITH PEPTIDE LINKER (GGGSGGGG) FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEI
  • MMUNOGLOBULIN G4 SCFV-H-CH2-CH3_SCFV, ANTI-(HOMO SAPIENS PDCD1 (PROGRAMMED CELL DEATH 1, PD1, PD-1, CD279)) AND ANTI-(HOMO SAPIENS CTLA4 (CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4, CD152)), CHIMERIC, HOMO SAPIENS AND HUMANIZED MONOCLONAL ANTIBODY, TET
External IDs
  • AEX-1344
  • AEX1344
  • MGD 019
  • MGD019

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
JM802R57SA
CAS number
2416595-46-3

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
2RecruitingTreatmentAndrogen Resistant Prostatic Cancer / Androgen-Independent Prostatic Cancer / Androgen-Independent Prostatic Neoplasms / Androgen-Insensitive Prostatic Cance / Hormone Refractory Prostatic Cancer / Immune Checkpoints Inhibitors / Immunotherapy / Inhibitory Checkpoint Molecule / Recurrent Prostate Cancer1somestatusstop reasonjust information to hide
2RecruitingTreatmentCervical Cancer / Metastatic Cancer1somestatusstop reasonjust information to hide
1Active Not RecruitingTreatmentAdult Solid Tumor / Advanced Malignant Neoplasm / Colorectal Cancer / Cutaneous Melanoma / Metastatic Prostate Cancer / Squamous Cell Non-small Cell Lung Cancer1somestatusstop reasonjust information to hide
1RecruitingTreatmentAdvanced Solid Tumors / Castration Resistant Prostate Cancer / Epithelial Ovarian Cancer / Liver Cancer / Malignant Melanoma / Pancreatic Ductal Adenocarcinoma (PDAC) / Renal Cell Carcinoma (RCC)1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at June 27, 2024 15:50 / Updated at June 28, 2024 04:46